Progress Made In MDL Of Xarelto Lawsuits

July 03, 2016 – – TheProductLawyers.com offers insight on the progress of the more than 2,800 lawsuits brought against Xarelto and its manufacturers—Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) and Bayer AG. The plaintiffs presented common allegations of undue risk associated with taking the anticoagulant and asserted that the drug was responsible for significant levels of injury. The overwhelming complexity of so many litigants prompted lawyers to petition the U.S. Judicial Panel on Multidistrict Litigation (JPML) for consolidation.

In December of 2015, the JPML issued a verdict in favor of consolidation, creating multidistrict litigation (MDL) No. 2592. Their supporting rationale stated that the consolidation would conserve time and resources for all parties, avoid the confusion created by different verdicts from different judges, and expedite the process of justice. To this end, they appointed Judge Eldon Fallon to preside over the case in the Eastern District of Louisiana. While all parties are currently selecting bellwether cases to further streamline the process of justice, the cases move steadily towards their court dates.

In 2011, the U.S. Food and Drug Administration conferred its approval of the new-generation anticoagulant. Initially, both the public reception and that of the medical community was warm. The drug was approved first to treat pulmonary embolism and deep vein thrombosis, as well as prevent clots in those recovering from hip or knee replacement surgeries. Soon afterward, it was also approved for use as a stroke preventative in patients with atrial fibrillation. However, due to rising concerns about the safety of Xarelto and claims of serious injuries as a result of use, the FDA has issued two black box warnings against the drug. These are the most severe marks of censure issued by the FDA and precede absolute recall of a product from the market.

Plaintiffs in both MDL 2592 and a mass tort program of 550 suits slated to be heard by the Philadelphia Court of Common Pleas contend that they were placed at a heightened risk of catastrophic bleeding episodes, systemic damage as a result, and in some cases, death. They further claim that the manufacturers were negligent in their duty to apprise both doctors and the public of potential risks associated with Xarelto.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011168